Cagent Vascular Initiates the Serranator® POINT FORCE Observational Registry

Study Will Enroll a Minimum of 500 Patients Across 30 United States Centers, Demonstrating the Benefits of Cagent’s Unique Serration Balloon Angioplasty Technology in Real-World Clinical Cases WAYNE, Penn., January 28, 2025 – Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the start of the POINT FORCE Registry, a post-market clinical follow-up study of the Serranator® PTA Serration Balloon Catheter. This prospective, multicenter, single-arm study will enroll a minimum of 500 subjects at up to 30 centers i